Drugs / M4112
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03306420 | Oct 2017 → Jan 2019 | cancer of unknown primary site | EMD Serono Research & Development Institute, Inc. | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | M4112 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03306420 ↗ |
| Route | Oral | “Participants received an oral dose of 100 milligrams (mg) M4112” NCT03306420 ↗ |